Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
|
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [41] Druggable aberrations in solid tumors: an overview on ALK and ROS-1 status
    Cona, M. S.
    Indini, A.
    Testi, A.
    Cresta, S.
    Signorelli, D.
    Garassino, M. C.
    Sinno, V.
    Sesana, S.
    Pelosi, G.
    de Braud, F. G.
    Damian, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 142 - 142
  • [42] Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement
    Zhang, Chao
    Li, Shao-lei
    Nie, Qiang
    Dong, Song
    Shao, Yang
    Yang, Xue-ning
    Wu, Yi-long
    Yang, Yue
    Zhong, Wen-zhao
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 726 - 731
  • [43] Biomarkers that currently affect clinical practice in lung cancer: EGFR ALK, ET, ROS-1, and KRAS
    Korpanty, Grzegorz J.
    Graham, Donna M.
    Vincent, Mark D.
    Leigh, Natasha B.
    FRONTIERS IN ONCOLOGY, 2014, 4 : 1 - 26
  • [44] Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement
    Rafee, Shereen
    Elamin, Yasir Y.
    Joyce, Eimear
    Toner, Mary
    Flavin, Richard
    McDermott, Ronan
    Sheehy, Niall
    Hennessy, Bryan
    O'Byrne, Kenneth
    Gleeson, Noreen
    Osman, Nemer
    TUMORI, 2015, 101 (02) : E35 - E39
  • [45] Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients
    Lan Song
    Zhenchen Zhu
    Huanwen Wu
    Wei Han
    Xin Cheng
    Ji Li
    Huayang Du
    Jing Lei
    Xin Sui
    Wei Song
    Zheng-yu Jin
    European Radiology, 2021, 31 : 2034 - 2047
  • [46] Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement
    Bitar, Lela
    Seiwerth, Fran
    Ljubicic, Lidija
    Bacelic-Gabelica, Ana
    Srdic, Drazena
    Korsic, Marta
    Badovinac, Sonja
    Plestina, Sanja
    Samarzija, Miroslav
    Jakopovic, Marko
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [47] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ROS1 GENE REARRANGEMENT
    Ou, S. I.
    Camidge, D. R.
    Engelman, J.
    Clark, J.
    Tye, L.
    Wilner, K.
    Stephenson, P.
    Varella-Garcia, M.
    Iafrate, A.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 389 - 389
  • [48] Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients
    Song, Lan
    Zhu, Zhenchen
    Wu, Huanwen
    Han, Wei
    Cheng, Xin
    Li, Ji
    Du, Huayang
    Lei, Jing
    Sui, Xin
    Song, Wei
    Jin, Zheng-yu
    EUROPEAN RADIOLOGY, 2021, 31 (04) : 2034 - 2047
  • [49] Intestinal Metastasis from Primary ROS1-Positive Lung Adenocarcinoma Patients Responding to Crizotinib
    Chen, H.
    Zhu, Y.
    Li, X.
    Wu, L.
    Du, K.
    Wang, W.
    Xu, C.
    Fang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1044 - S1045
  • [50] Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
    Gibson, A.
    Dean, M.
    Elegbede, A. J.
    Pabani, A.
    Bebb, G. J.
    Cheung, W. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S402 - S402
12345